Randy Schreckhise

CEO & Co-founder
Randy has made contributions to a number of approved therapeutics and therapeutic candidates through finance, business development, operations and strategy roles at aTyr Pharma, Abilita Bio, Trius Therapeutics, Ardea Biosciences, Human Genome Sciences and ZymoGenetics, and also through work in project management, protein biochemistry and genetics during his eight years at ZymoGenetics. Earlier in his career he worked in the Basic Sciences and Clinical Divisions at The Fred Hutchinson Cancer Research Center, where he studied meiotic recombination of the fission yeast S. pombe and also developed DNA-based assays for the detection of invasive fungal disease . For the past five years, Randy has been an active member of The San Diego Entrepreneurs Exchange, and currently serves as President and Board Member. He received an MBA with a concentration in finance from Seattle University and a BS in microbiology with a minor in molecular biology from Washington State University, where he was a Howard Hughes Undergraduate Research Fellow.

Mark Sullivan, MD, MPH

Dr. Mark Sullivan holds undergraduate degrees in microbiology and molecular biology through Washington State University and advanced degrees of Doctor of Medicine and Master of Public Health both through the University of Washington. He is a board certified physician in three specialties of Internal Medicine, Critical Care Medicine, and Occupational/Environmental Medicine with special interest in toxic exposure assessment and treatment. Dr. Sullivan completed his MPH research thesis on the association between transition metal components of < 2.5 micron particulate matter (PM 2.5) and lung function and density as potentially relates to chronic obstructive pulmonary disease (COPD) prevalence. Past research experience includes identifying the structure of the working genome of the Human Foamy Retrovirus at Fred Hutchinson Cancer Research Center, and helping to identify the Alzheimer’s and Werner’s disease gene locus at the University of Washington.

David Giegel, PhD

Chief Scientific Officer & SAB Chair
Dr. Giegel brings more than twenty-five years of expertise in drug discovery and development to August Therapeutics. He most recently served as President and Chief Scientific Officer of TissueNetix, Inc., a company he founded. Prior to TissueNetix, Dr. Giegel was President and Chief Scientific Officer of MicroStem. Previously, he was an Adjunct Associate Research Professor at San Diego State University, and was Entrepreneur-in-Residence at CONNECT, San Diego, where he mentored companies in the Springboard Program. Dr. Giegel also was Senior Director of the Molecular Sciences Group at Celgene, and held scientific leadership positions at MitoKor, Pfizer, and Warner-Lambert/Parke-Davis. He earned his Ph.D. in Biological Chemistry from the University of Michigan and a B.S. in Chemistry from Miami University in Ohio.

Lecya Tyaglo

Research Associate
Lecya is a graduate from UC Santa Cruz with a degree in molecular and cell developmental biology. While in Santa Cruz, she focused her studies in cancer genomics and genome sequencing. She also participated in the UC Santa Cruz Genomics Institute with the Treehouse Childhood Initiative analyzing cancer data, focusing on creating gene expression models to identify tumors that were driven by the same molecular pathways. Her aim as a growing scientist is to develop more effective and less toxic therapies.

Amy Arthur, PhD

Amy is an R&D Program and Alliance Management professional with over 17 years of successful, collaborative leadership and management, supporting the biotechnology and pharmaceutical industries from early research through lead optimization to development candidates. Her educational and research background encompassed chemistry, pharmacology and toxicology at Goucher College (bachelor’s degree), Dartmouth College (doctorate), the National Cancer Institute at the National Institutes of Health (postdoctoral fellowship), and a Research Professor in the Departments of Chemistry, and Pharmacology and Toxicology at Dartmouth College and Medical School. She began her biotechnology career in San Diego at Digital Gene Technologies, followed by Senomyx, where she established and headed the Program & Alliance Management Department for over 13 years, managing external collaborations with prominent companies in the food and beverage industry, supporting cross-functional research projects discovering small molecules that modulate taste receptors, and leading the development of flavor ingredients through pre-clinical toxicology, manufacturing, and regulatory submissions, which resulted in approval of 14 flavor ingredients at various stages of commercialization. She furthered her knowledge of research project management at Vertex Pharmaceuticals and is currently honing her business skills in Business Development at the global CRO Pharmaron, where she focuses on building strong client relationships and specializes in chaperoning startups through discovery biology, chemistry, CMC and  IND enabling studies.  She has 26 published manuscripts in peer reviewed journals and 2 published patents; was PI or Co-PI on 5 research grants; and received 10 awards for excellence in research and teaching.

Anthony Farina, PhD

Anthony received his BS in biochemistry from the University of California, Riverside and a PhD in biochemistry and chemistry from the University of California, San Diego and was a post doctoral scholar at the David Geffen School of Medicine at the Univeristy of California, Los Angeles. His area of expertise is focused around protein chemistry and synthetic biology. In addition to consulting for August Therapeutics, he is currently the CSO of Librede, Inc. a synthetic biology company focused on producing cannabidiol in microorganisms and has the first issued patent around complete biosynthesis of CBD in yeast.

Amir Fayyazuddin, PhD

Amir has over 20 years of experience in biomedical research and drug discovery with particular interest in genetics, genomics, neurobiology, and computational biology. He obtained his undergraduate degree in Mathematics from the University of Chicago followed by his PhD in Neurobiology, at the same institution, that focused on high-speed, precision reflex circuits that stabilize flight in flies. He then did post-doctoral research on ion channels, elucidating the structural basis of zinc modulation of NMDA receptors at the Ecole Normale Supérieure in Paris and characterizing behavioral and cellular effects of nicotinic acetylcholine receptor mutations at Baylor College of Medicine in Houston. More recently at Dart Neuroscience in San Diego he identified drug targets and biomarkers for memory formation and diseases that affect this process using experimental and computational approaches.

Lynda Groocock, PhD

Lynda brings her extensive experience in molecular biology and protein expression to the team. Prior to working with August Therapeutics, she held a Scientist position at Abilita Bio, where she coordinated molecular biology and protein production for therapeutic discovery programs for highly differentiated stabilized membrane proteins. Lynda’s diverse scientific background stems from post-doctoral research at TSRI where she worked on SUMO and Ubiquitin signaling pathways within the DNA damage response. Lynda received a PhD in Cell Biology from the University of Edinburgh, UK, and a MBioChem from the University of Bath, U.K. She has publications in Cell, Nature Communications, EMBO Reports, MBC and JCS.

Sascha Nicklisch, PhD

Sascha joined AT as ad-hoc Consultant in April 2017 and is currently an Assistant Professor in the Department of Environmental Toxicology at UC Davis. He received both his MS in Biological Sciences (2005) and his PhD in Protein Biochemistry (2008) from the University of Cologne, Germany. Sascha has been a Postdoctoral Research Fellow in the Experimental Physics Department at the University of Osnabrück, Germany (2008-2009), in the Marine Science Institute at UC Santa Barbara (2010-2012) and at Scripps Institution of Oceanography at UC San Diego (2012-2018). He worked as Senior Analytical Biochemist at Pfenex Inc., San Diego (2018-2019) where he was Technical Lead of the Impurity Formation and Shelf-life Prediction Project for Biosimilar Drug Products. His main expertise is in expression, purification and structure-function analysis of soluble and membrane proteins. His research focuses on drug and chemical interactions with drug transporters and the development of novel sensors for low-cost and rapid detection of toxicants. Sascha has published 14 peer-reviewed articles and consulted for local and statewide projects on human and environmental toxicology, including the City of San Diego, UC Santa Barbara, Portland State University, and for the California Council on Science and Technology (CCST).